Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tumor heterogeneity complicates targeted cancer therapy, necessitating novel therapeutic targets.
• JWA (ADP ribosylation factor-like GTPase 6 interacting protein 5) is a microtubule-associated protein and environmental response gene.
• Reduced JWA expression is observed across various malignancies and linked to patient survival outcomes.

Purpose of the Study:

• To review the structure and biological functions of JWA in the context of cancer.
• To examine therapeutic strategies targeting JWA.
• To explore future research directions for JWA in oncology.

Main Methods:

• Literature review of studies on JWA expression, function, and therapeutic potential in cancer.
• Analysis of existing evidence linking JWA to cancer hallmarks.
• Synthesis of information on JWA's role as a tumor suppressor.

Main Results:

• JWA acts as a tumor suppressor by inhibiting oncogenes and activating tumor suppressor genes.
• Low JWA expression is associated with increased angiogenesis, proliferation, metastasis, and chemotherapy resistance.
• JWA's expression levels correlate with overall survival in cancer patients.

Conclusions:

• JWA plays a critical role in suppressing tumor progression through multiple mechanisms.
• Targeting JWA presents a promising therapeutic strategy for various cancers.
• Further investigation into JWA's functions and therapeutic applications is warranted.